The Impact of Non-alcoholic Fatty Liver Disease on Incident Type 2 Diabetes Mellitus in Non-overweight Individuals
Overview
Authors
Affiliations
Background & Aims: The aim of this study was to evaluate the impact of non-alcoholic fatty liver disease (NAFLD) on incident type 2 diabetes mellitus (T2DM) in non-overweight individuals with NAFLD.
Methods: A population-based retrospective cohort study of 4629 participants who were enrolled in a health check-up programme for more than 10 years. A standardized questionnaire and abdominal ultrasonography were used to diagnose NAFLD. A cut-off point of BMI 23 kg/m(2) was used to define overweight (≥23.0 kg/m(2)) or non-overweight (<23.0 kg/m(2)). The primary outcome was incident T2DM.
Results: Over a mean follow-up of 12.8 years, 351 participants (7.6%) developed T2DM. The incidence rate of T2DM was 3.2% in the non-overweight without NAFLD group, 14.4% in the non-overweight with NAFLD group, 8.0% in the overweight without NAFLD group and 26.4% in the overweight with NAFLD group. The adjusted hazard ratios for incident T2DM compared with the non-overweight without NAFLD group were as follows: 3.59 (95% CI: 2.14-5.76) in the non-overweight with NAFLD group, 1.99 (95% CI: 1.47-2.69) in the overweight without NAFLD group and 6.77 (95% CI: 5.17-8.91) in the overweight with NAFLD group. The adjusted hazard ratio in the non-overweight with NAFLD group was significantly higher than that in the overweight without NAFLD group or that in the non-overweight without NAFLD group.
Conclusions: Non-overweight individuals with NAFLD had a high risk of incident T2DM. Diagnosis of NAFLD is important in non-overweight individuals, and therefore it might be necessary to follow their health conditions on a long-term basis after detection of NAFLD.
Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D Clin Mol Hepatol. 2024; 31(1):74-89.
PMID: 39439408 PMC: 11791619. DOI: 10.3350/cmh.2024.0631.
Cao C, Mo Z, Han Y, Luo J, Hu H, Yang D Sci Rep. 2024; 14(1):6056.
PMID: 38480862 PMC: 10937981. DOI: 10.1038/s41598-024-56555-8.
Cao L, An Y, Liu H, Jiang J, Liu W, Zhou Y BMC Med. 2024; 22(1):101.
PMID: 38448943 PMC: 10919055. DOI: 10.1186/s12916-024-03315-0.
Chai J, Wang N, Chen L, Bai J, Zhang J, Zhang G Int J Mol Sci. 2023; 24(23).
PMID: 38069122 PMC: 10706401. DOI: 10.3390/ijms242316799.
Li N, Xang W, Wu S, Li D, Chang M, Xie C Front Endocrinol (Lausanne). 2023; 14:1173757.
PMID: 37435491 PMC: 10332153. DOI: 10.3389/fendo.2023.1173757.